⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6186727 | 0.74 | — | — | |
| SCHEMBL17307519 | 0.70 | — | — | |
| SCHEMBL3672880 | 0.69 | — | — | |
| SCHEMBL16634400 | 0.69 | — | — | |
| SCHEMBL17629781 | 0.62 | — | — | |
| SCHEMBL10343777 | 0.61 | — | — | |
| SCHEMBL18587487 | 0.60 | — | — | |
| SCHEMBL3602470 | 0.57 | — | — | |
| SCHEMBL7288781 | 0.57 | — | — | |
| SCHEMBL4079948 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106687458-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2020-10-27 | — | — | CN | disclosed |
| EP-3197872-B1 | (2H)-2-OXOPYRIDINES AS FAKTOR XIA-INHIBITORS FOR TREATING THROMBOTIC DISEASES | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| EP-3197872-B1 | (2H)-2-OXOPYRIDINES AS FAKTOR XIA-INHIBITORS FOR TREATING THROMBOTIC DISEASES | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-10167280-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-01 | — | — | US | disclosed |
| EP-3197873-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2018-10-24 | — | — | EP | disclosed |
| US-20170298052-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298052-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298052-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-19 | — | — | US | disclosed |
| US-20170291892-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-12 | — | — | US | disclosed |
| US-20170291892-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-12 | — | — | US | disclosed |
| US-20170291892-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-12 | — | — | US | disclosed |
| EP-3197873-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197872-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2017-08-02 | — | — | EP | disclosed |
| CN-106687458-A | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2017-05-17 | — | — | CN | disclosed |
| WO-2016046164-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046166-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046164-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046166-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |